NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $17.79 -0.63 (-3.42%) (As of 04:32 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Fulgent Genetics Stock (NASDAQ:FLGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fulgent Genetics alerts:Sign Up Key Stats Today's Range$17.65▼$18.4950-Day Range$18.42▼$22.9152-Week Range$17.65▼$30.68Volume294,010 shsAverage Volume181,666 shsMarket Capitalization$544.20 millionP/E RatioN/ADividend YieldN/APrice Target$28.50Consensus RatingHold Company OverviewFulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More… Elon Musk has put himself in their crosshairs (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Fulgent Genetics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreFLGT MarketRank™: Fulgent Genetics scored higher than 84% of companies evaluated by MarketBeat, and ranked 181st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fulgent Genetics are expected to decrease in the coming year, from ($1.46) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulgent Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.25% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 4.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.67 Percentage of Shares Shorted3.25% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 4.51%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.34 News SentimentFulgent Genetics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,717.00 in company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Stock News HeadlinesPiper Sandler Cuts Fulgent Genetics (NASDAQ:FLGT) Price Target to $22.00November 13 at 2:43 AM | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Downgraded by StockNews.com to "Sell"November 13 at 1:51 AM | americanbankingnews.comElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.November 14, 2024 | Porter & Company (Ad)Fulgent Genetics price target lowered to $22 from $26 at Piper SandlerNovember 13 at 1:50 AM | markets.businessinsider.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2024 Earnings Call TranscriptNovember 13 at 1:50 AM | msn.comFulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call TranscriptNovember 11 at 3:05 AM | seekingalpha.comCompanies Like Fulgent Genetics (NASDAQ:FLGT) Are In A Position To Invest In GrowthNovember 10, 2024 | finance.yahoo.comFulgent Genetics Reports Q3 2024 Financial PerformanceNovember 10, 2024 | markets.businessinsider.comSee More Headlines FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $28.91 at the beginning of 2024. Since then, FLGT stock has decreased by 37.3% and is now trading at $18.12. View the best growth stocks for 2024 here. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings results on Friday, August, 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.45. The company's quarterly revenue was up 4.7% on a year-over-year basis. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' top institutional shareholders include Charles Schwab Investment Management Inc. (0.81%), Principal Financial Group Inc. (0.32%), Empowered Funds LLC (0.30%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.15%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET). Company Calendar Last Earnings8/02/2024Today11/14/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,184Year Founded2011Price Target and Rating Average Stock Price Target$28.50 High Stock Price Target$35.00 Low Stock Price Target$22.00 Potential Upside/Downside+58.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-59.39% Pretax Margin-68.09% Return on Equity-1.81% Return on Assets-1.66% Debt Debt-to-Equity RatioN/A Current Ratio4.41 Quick Ratio5.27 Sales & Book Value Annual Sales$289.21 million Price / Sales1.90 Cash Flow$3.05 per share Price / Cash Flow5.90 Book Value$37.10 per share Price / Book0.48Miscellaneous Outstanding Shares30,590,000Free Float20,873,000Market Cap$550.01 million OptionableOptionable Beta1.51 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:FLGT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.